@article{fdi:010057154,
  title = {{D}rug resistance mutations of {HIV} type 1 non-{B} viruses to integrase inhibitors in treatment-naive patients from sub-{S}aharan countries and discordant interpretations},
  author = {{M}onleau, {M}arjorie and {A}ghokeng {F}obang, {A}velin and {N}kano, {B}.{A}. and {C}haix, {M}.{L}. and {P}eeters, {M}artine},
  editor = {},
  language = {{ENG}},
  abstract = {{T}he routine use of integrase inhibitors in sub-{S}aharan {A}frica where {HIV}-1 non-{B} viruses predominate is limited, but evaluating their effectiveness on {HIV}-1 subtypes and {CRF}s that circulate in this region is essential. {W}e here analyzed 97 integrase sequences from {HIV}-1 non-{B}-infected individuals from {A}frican countries. {U}sing currently available interpretation algorithms ({ANRS}, {FTIV}db, and {R}ega), we identified the presence of mutations at nine resistance-associated positions including {L}74{M} (3.1%), {T}97{A} (9.3%), {K}156{N} (2.1%), {E}157{Q} (5.2%), {G}163{K} (1.0%), {T}206{S} (48.5%), {S}230{N} (1.0%), {D}232{N} (1.0%), and {R}236{K} (1.0%). {A}ll but one ({E}157{Q}) were considered as accessory resistant mutation by the algorithms. {E}157{Q} identified in 5% of patients tested (5/97) was selected by the {ANRS} algorithm as a primary mutation, which alone can confer resistance to raltegravir. {T}hese results illustrated the need of further in vitro and clinical studies involving non-{B} viruses to better understand the real significance of observed mutations and harmonize interpretations.},
  keywords = {},
  booktitle = {},
  journal = {{A}ids {R}esearch and {H}uman {R}etroviruses},
  volume = {28},
  numero = {9},
  pages = {957--960},
  ISSN = {0889-2229},
  year = {2012},
  DOI = {10.1089/aid.2011.0326},
  URL = {https://www.documentation.ird.fr/hor/fdi:010057154},
}